| 1 |
Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
|
| 2 |
ClinicalTrials.gov (NCT03674814) Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
|
| 3 |
ClinicalTrials.gov (NCT02207504) Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
|
| 4 |
ClinicalTrials.gov (NCT03328364) A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
|
| 5 |
ClinicalTrials.gov (NCT01597193) Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
|
| 6 |
ClinicalTrials.gov (NCT03123978) Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
|
| 7 |
ClinicalTrials.gov (NCT04179864) A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
|
| 8 |
ClinicalTrials.gov (NCT02500901) Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
|
| 9 |
ClinicalTrials.gov (NCT02457910) Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
|
| 10 |
ClinicalTrials.gov (NCT02555189) Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
|
| 11 |
ClinicalTrials.gov (NCT02532114) Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
|
| 12 |
ClinicalTrials.gov (NCT02935205) Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
|
| 13 |
ClinicalTrials.gov (NCT02012296) Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
|
| 14 |
ClinicalTrials.gov (NCT02125084) Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
|
| 15 |
ClinicalTrials.gov (NCT02138799) A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men
|
| 16 |
ClinicalTrials.gov (NCT03751436) Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
|
| 17 |
ClinicalTrials.gov (NCT03999515) Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
|
| 18 |
ClinicalTrials.gov (NCT03295565) Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
|
| 19 |
ClinicalTrials.gov (NCT05393791) Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
|
| 20 |
ClinicalTrials.gov (NCT02254785) Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
|
| 21 |
ClinicalTrials.gov (NCT02525068) A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC
|
| 22 |
ClinicalTrials.gov (NCT05726292) A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
|
| 23 |
ClinicalTrials.gov (NCT01990196) Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
|
| 24 |
ClinicalTrials.gov (NCT04015622) PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
|
| 25 |
ClinicalTrials.gov (NCT01885949) Tivozanib + Enzalutamide in Adv Prostate Cancer
|
| 26 |
ClinicalTrials.gov (NCT03336983) Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients
|
| 27 |
ClinicalTrials.gov (NCT02452008) Study of TGF- Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
|
| 28 |
ClinicalTrials.gov (NCT03939689) Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
|
| 29 |
ClinicalTrials.gov (NCT02955394) Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
|
| 30 |
ClinicalTrials.gov (NCT02430480) Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
|
| 31 |
ClinicalTrials.gov (NCT01547299) Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
|
| 32 |
ClinicalTrials.gov (NCT02064582) Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
|
| 33 |
ClinicalTrials.gov (NCT04332744) Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
|
| 34 |
ClinicalTrials.gov (NCT06136650) A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
|
| 35 |
ClinicalTrials.gov (NCT02288247) A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
|
| 36 |
ClinicalTrials.gov (NCT04409288) Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
|
| 37 |
ClinicalTrials.gov (NCT02446444) Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
|
| 38 |
ClinicalTrials.gov (NCT02319837) Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
|
| 39 |
ClinicalTrials.gov (NCT01995513) Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
|
| 40 |
ClinicalTrials.gov (NCT02918968) Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
|
|
|
|
|
|
|
